Chirag B. Shah, PharmD, MD

Onset and Resolution of Key Adverse Events in Valbenazine-Treated Patients with Tardive Dyskinesia: Pooled Post Hoc Analyses from Two Long-Term Clinical Trials

Background: Tardive dyskinesia (TD) is a persistent and potentially disabling movement disorder associated with prolonged exposure to antipsychotics and other dopamine receptor blocking a...

Jean-Pierre Lindenmayer , MD;

Stephen Marder , MD;

Tara Carmack , MS;

Angel Angelov , MD;

Chirag B. Shah , PharmD, MD;

Leslie Lundt , MD;

10/08/2020

Original Research

Efficacy of Polyhexamethylene Biguanide-containing Antimicrobial Foam Dressing Against MRSA Relative to Standard Foam Dressing

09/15/2009

Chirag B. Shah , PharmD, MD;

Steve T. Fisher ;

Kelly R. Kirker ;

Diane McGhee ;

Garth A. James ;

09/15/2009

Wounds

TD360: Outcomes of a Tardive Dyskinesia Educational Curriculum – A Focus on Quality of Life, Increased Detection and Novel Treatments

TD360 Background

Paula Williams ;

Michelle Stewart ;

Chirag B. Shah , PharmD, MD;

Rakesh Jain , MD, MPH, RD;

11/01/2020

Understanding the evolving continuing medical education needs of physicians managing patients with TD

This study sought to understand the evolving continuing medical education (CME) needs of physicians managing patients with tardive dyskinesia (TD). A case-based survey was developed, and ...

Sylvie Stacy , MD, MPH;

Shereta Wiley , MPH;

Khodayar Farahmand , PharmD;

Wendy Cerenzia , MS;

Chirag B. Shah , PharmD, MD;

Leslie Lundt , MD;

10/08/2020